Radiopharmaceutical · Kills target cells, directed at programmed cell death 1 ligand 1 (CD274) · developed by Radiopharm Theranostics
Lutetium Lu 177 anti-PD-L1 nanobody RAD204 is a radioimmunoconjugate in which a nanobody binds PD-L1 on tumor cells and delivers beta radiation from lutetium-177 to those cells. It is also intended for imaging PD-L1 expression by SPECT/CT. It is being studied in non-small cell lung cancer, small cell lung cancer, triple negative breast cancer, melanoma, head and neck squamous cell carcinoma, and endometrial cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT06305962 | Early Phase 1 | PDL1 Gene Mutation | Recruiting | RADX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Cutaneous MelanomaEndometrial CancerHNSCCMmr DeficiencyMSI-HighNon Small Cell Lung CancerPDL1 Gene MutationSmall Cell Lung Cancer ( SCLC )TNBC, Triple Negative Breast Cancer
Updated Oct 25, 2026. Something wrong or missing? Report it on the RADX page.
See RADX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
RADX catalysts and pipeline →